Skip to main content
VIVOZON PHARMACEUTICAL CO., LTD. logo

VIVOZON PHARMACEUTICAL CO., LTD. — Investor Relations & Filings

Ticker · 082800 ISIN · KR7082800004 KO Manufacturing
Open in API
Filings indexed 590 across all filing types
Latest filing 2023-10-05 Declaration of Voting R…
Country KR South Korea
Listing KO 082800

About VIVOZON PHARMACEUTICAL CO., LTD.

https://www.vivozon.com/

VIVOZON PHARMACEUTICAL CO., LTD. is a research and development company specializing in the discovery and commercialization of innovative drugs, with a primary focus on pain and central nervous system (CNS) diseases. The company utilizes a multi-target drug development platform to create new chemical entities that act on multiple targets to achieve synergistic efficacy. This approach integrates efficacy-based screening from the early stages of discovery to identify candidate substances with a high potential for successful clinical development. Its lead pipeline candidate is Opiranserin (VVZ-149), a first-in-class, non-narcotic injectable analgesic for post-operative pain management. The company is actively expanding its pipeline to address a broader range of unmet medical needs within the CNS field.

Recent filings

Filing Released Lang Actions
임시주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled '임시주주총회결과' (Extraordinary General Meeting Results) and lists the resolutions passed during the meeting held on 2023-10-05. It explicitly details the outcome of shareholder votes (approval of articles of incorporation changes and stock consolidation). This fits the definition of a Declaration of Voting Results & Voting Rights Announcement (DVA).
2023-10-05 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Major Shareholding Notification Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean regulatory authorities (Financial Supervisory Service/KRX). It details a change in shareholding (a decrease of 5,000,000 shares due to a gift/transfer) by a major shareholder, 'Vaultea, Inc.', in the company 'Vivozon Pharmaceutical'. This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) as it tracks changes in significant ownership levels.
2023-09-25 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details changes in share ownership (specifically a 5% rule filing) by a major shareholder (Vaultea, Inc.) in Vivozon Pharmaceutical. This type of filing is categorized as a Major Shareholding Notification (MRQ) in the provided schema.
2023-09-25 Korean
자기주식취득결과보고서
Transaction in Own Shares Classification · 100% confidence The document is a '자기주식취득결과보고서' (Report on the Results of Treasury Stock Acquisition) filed with the Financial Supervisory Service (FSS) in South Korea. It details the acquisition of treasury shares by Vivozon Pharmaceutical, specifically noting the acquisition date, quantity, and the reason (donation from a major shareholder). This falls under the category of a company reporting its own share transactions, which corresponds to the 'Transaction in Own Shares' (POS) classification.
2023-09-21 Korean
주주총회소집공고
AGM Information Classification · 98% confidence The document is a formal 'Notice of Extraordinary General Meeting' (임시주주총회소집공고) issued by Vivozon Pharmaceutical. It details the meeting agenda, including proposed amendments to the articles of incorporation and a stock consolidation (share split/reverse split) proposal. This document serves as the official proxy statement and information package provided to shareholders to inform them of the meeting and solicit their votes. According to the provided definitions, this fits the 'Proxy Solicitation & Information Statement' (PSI) category.
2023-09-20 Korean
전환가액의조정(제20회차 CB)
Capital/Financing Update Classification · 100% confidence The document is a formal regulatory filing regarding the adjustment of the conversion price for convertible bonds (CB) issued by Vivozon Pharmaceutical. It details the change in conversion price, the number of convertible shares, and the underlying reasons (market price decline). This type of disclosure regarding capital structure changes and debt-to-equity conversion terms falls under the 'Capital/Financing Update' category.
2023-09-20 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.